Structures by: Caira M. R.
Total: 112
None
C19H28N2O7S2,0.5(H2O1)
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=9.4990(13)Å b=10.5848(15)Å c=43.643(6)Å
α=90.00° β=90.00° γ=90.00°
2-methoxyestradiol chloroform solvate 1:2
C19H26O3,2(C1H1Cl3)
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=6.3150(2)Å b=9.3352(3)Å c=11.1622(5)Å
α=104.386(2)° β=95.464(2)° γ=107.774(2)°
2-methoxyestradiol
C19H26O3
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=6.2540(2)Å b=11.2919(3)Å c=11.5524(4)Å
α=90.00° β=97.3550(10)° γ=90.00°
Thalidomide; N-(2,6-dioxo-3-piperidyl)phalimide
C13H10N2O4
Journal of Chemical Crystallography (1994) 24, 1 95-99
a=20.679(5)Å b=8.042(2)Å c=14.162(5)Å
α=90° β=102.86(3)° γ=90°
None
C28H12Cl4O8
Organic letters (2008) 10, 11 2119-2122
a=13.2927(3)Å b=13.2927(3)Å c=7.3547(2)Å
α=90.00° β=90.00° γ=90.00°
None
C21H9F3O6.C3H7NO
Organic letters (2008) 10, 11 2119-2122
a=9.5721(7)Å b=10.0848(7)Å c=12.5819(6)Å
α=69.849(4)° β=73.108(4)° γ=75.513(4)°
9,9'(Biphenyl-4,4'-diyl)difluoren-9-ol
C38H26O2
Organic & biomolecular chemistry (2004) 2, 16 2299-2304
a=5.80020(10)Å b=14.4736(3)Å c=15.7510(3)Å
α=90.00° β=91.1410(10)° γ=90.00°
9,9'-(Biphenyl-4,4'-diyl)bis(fluoren-9-ol). 4(N,N- dimethylacetamide) clathrate
C38H26O2.4(C4H9NO)
Organic & biomolecular chemistry (2004) 2, 16 2299-2304
a=10.29610(10)Å b=14.9893(2)Å c=17.8825(3)Å
α=108.2550(10)° β=91.5240(10)° γ=109.2840(10)°
9,9'-(Biphenyl-4,4'-diyl)bis(fluoren-9-ol). 2(N,N- dimethylacetamide) clathrate
C38H26O2.2(C4H9NO)
Organic & biomolecular chemistry (2004) 2, 16 2299-2304
a=7.9629(3)Å b=9.0266(4)Å c=13.5092(7)Å
α=77.015(2)° β=83.033(2)° γ=84.212(2)°
9,9'-(Biphenyl-4,4'-diyl)bis(fluoren-9-ol). 3(1,4-dioxane) clathrate
C38H26O2.3(C4H8O2)
Organic & biomolecular chemistry (2004) 2, 16 2299-2304
a=13.1096(3)Å b=12.8883(2)Å c=12.0038(2)Å
α=90.00° β=92.2470(10)° γ=90.00°
9,9'-(Biphenyl-4,4'-diyl)bis(flouren-9-ol). 2(methyl ethyl ketone) clathrate
C38H26O2.2(C4H8O)
Organic & biomolecular chemistry (2004) 2, 16 2299-2304
a=7.79930(10)Å b=21.9845(4)Å c=21.0296(4)Å
α=90.00° β=94.5520(10)° γ=90.00°
(1S,2S,7R,8S,9R)-8-hydroxymethyl-10,12-dioxatricyclo- (7.2.1.027)dodec-4-ene
C11H16O3
Organic & Biomolecular Chemistry (2009) 7, 17 3527-3536
a=7.475(1)Å b=8.234(1)Å c=16.061(2)Å
α=90.00° β=90.00° γ=90.00°
2,2'-dihydroxyl-1,1'-binaphthyl diquinoline
C20H14O22C9H7N1
Organic & biomolecular chemistry (2004) 2, 5 655-659
a=18.1633(8)Å b=11.0249(5)Å c=14.0928(8)Å
α=90.00° β=97.171(2)° γ=90.00°
2,2-dihydroxyl-1,1'-binaphthyl di-8-methylquinoline
C20H14O22C10H9N1
Organic & biomolecular chemistry (2004) 2, 5 655-659
a=14.4495(3)Å b=11.0481(3)Å c=19.6571(6)Å
α=90.00° β=105.1000(10)° γ=90.00°
2,2-dihydroxyl-1,1'-binaphthyl di-2-methylquinoline
C20H14O22C10H9N1
Organic & biomolecular chemistry (2004) 2, 5 655-659
a=14.8402(3)Å b=10.5377(2)Å c=9.7304(2)Å
α=90.00° β=99.4430(10)° γ=90.00°
2,2'-dihydroxyl-1,1'-binaphthyl 6-methylquinoline clathrate
C20H14O22.5C10H9N1
Organic & biomolecular chemistry (2004) 2, 5 655-659
a=8.83960(10)Å b=9.46950(10)Å c=21.6106(3)Å
α=94.6520(10)° β=98.0680(10)° γ=103.8220(10)°
Heptakis(2,6-di-O-methyl)-beta-cyclodextrin.6,7,8,9,10,10 - hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepin 3-oxide
C56H98O35,C9H6Cl6O3S,1.04(H2O)
New Journal of Chemistry (2012) 36, 10 2007
a=26.907(4)Å b=29.784(4)Å c=20.352(3)Å
α=90.00° β=90.00° γ=90.00°
2,3-bis-fluoren-9-ylidene-succinic acid acetone solvate (1:1)
C30H18O4.C3H6O
New Journal of Chemistry (2004) 28, 3 329
a=9.9117(2)Å b=14.1651(3)Å c=18.1568(5)Å
α=90.00° β=90.00° γ=90.00°
2,3-bis-fluoren-9-ylidene-succinic acid
C30H18O4
New Journal of Chemistry (2004) 28, 3 329
a=15.8893(3)Å b=9.7361(2)Å c=13.3280(2)Å
α=90.00° β=90.00° γ=90.00°
2,3-bis-fluoren-9-ylidene-succinic acid ethyl acetate solvate (1:1)
C30H18O4.C4H8O2
New Journal of Chemistry (2004) 28, 3 329
a=12.1730(1)Å b=12.3379(2)Å c=17.7792(2)Å
α=90.00° β=94.282(1)° γ=90.00°
C14H12ClIN2O4
C14H12ClIN2O4
CrystEngComm (2019)
a=8.3915(7)Å b=10.0389(8)Å c=10.2106(9)Å
α=111.275(8)° β=96.662(7)° γ=95.904(7)°
C14H13IN2O5
C14H13IN2O5
CrystEngComm (2019)
a=23.0873(10)Å b=9.6374(3)Å c=7.2450(3)Å
α=90.00° β=106.961(4)° γ=90.00°
C16H17IN2O4
C16H17IN2O4
CrystEngComm (2019)
a=8.1400(6)Å b=13.4654(5)Å c=16.3082(8)Å
α=90.00° β=90.00° γ=90.00°
Isonicotinamide
C6H6N2O
CrystEngComm (2019) 21, 5 843
a=9.8880(12)Å b=7.9929(9)Å c=15.1620(18)Å
α=90° β=90° γ=90°
(+)-(2R,3R)-tetraphenylbutane-1,2,3,4-tetraol /2-methylcyclohexanone (1:1)
C28H26O4,C7H12O
Chem.Commun. (2014) 50, 13353
a=10.3843(3)Å b=15.2193(3)Å c=18.2734(4)Å
α=90° β=90° γ=90°
None
C28H26O4,C7H12O1
Chem.Commun. (2014) 50, 13353
a=8.181(2)Å b=9.952(3)Å c=10.163(3)Å
α=79.296(6)° β=68.813(5)° γ=65.825(5)°
(+)-(2R,3R)-tetraphenylbutane-1,2,3,4-tetraol/3-methylcyclohexanone (1:1)
C28H26O4,C7H12O
Chem.Commun. (2014) 50, 13353
a=12.4493(6)Å b=8.2368(4)Å c=13.9466(7)Å
α=90.00° β=95.843(2)° γ=90.00°
Bis(beta-cyclodextrin) bis(4-hydroxybenzoic acid methyl ester) clathrate hydrate (monoclinic form)
C42H70O35.C8H8O3.7.2H2O
Chemical Communications (2003) 16 2058
a=18.8632(4)Å b=24.4542(5)Å c=15.5942(5)Å
α=90.00° β=110.668(1)° γ=90.00°
Bis(Beta-cyclodextrin) bis(4-hydroxybenzoic acid methyl ester) clathrate hydrate (triclinic form)
(C42H70O35)2.(C8H8O3)2.28H2O
Chemical Communications (2003) 16 2058
a=18.0187(3)Å b=15.3431(4)Å c=15.4140(3)Å
α=103.464(1)° β=113.122(1)° γ=99.254(1)°
Heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin
C63H112O35
Chemical Communications (2004) 19 2216-2217
a=15.9509(1)Å b=16.5772(1)Å c=28.9413(2)Å
α=90.00° β=90.00° γ=90.00°
Heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin trihydrate
C63H112O35.3H2O
Chemical Communications (2004) 19 2216-2217
a=16.2051(1)Å b=16.2870(1)Å c=30.0989(3)Å
α=90.000° β=90.000° γ=90.000°
None
C34H36O2.2(C3H7NO).2(C2H6OS)
Chemical Communications (2001) 20 2128
a=9.1425(3)Å b=9.1730(3)Å c=14.2730(10)Å
α=71.3560(10)° β=81.2290(10)° γ=69.9380(10)°
None
C34H36O2.3(C3H7NO).1(C2H6OS)
Chemical Communications (2001) 20 2128
a=9.0806(4)Å b=9.0909(3)Å c=14.6632(7)Å
α=72.2940(10)° β=87.6600(10)° γ=70.299(2)°
None
C34H36O2.4(C3H7NO)
Chemical Communications (2001) 20 2128
a=8.9414(3)Å b=9.0806(4)Å c=14.9350(10)Å
α=91.307(2)° β=105.523(2)° γ=110.189(3)°
None
C34H36O2.4(C2H6OS)
Chemical Communications (2001) 20 2128
a=9.0330(18)Å b=9.1302(18)Å c=14.404(3)Å
α=72.87(3)° β=80.07(3)° γ=71.66(3)°
None
C34H36O2
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=16.6711(3)Å b=10.6712(2)Å c=24.3875(5)Å
α=90.00° β=101.4350(10)° γ=90.00°
None
C34H36O2.4(C3H7NO)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=9.0806(3)Å b=8.9414(4)Å c=14.9350(10)Å
α=74.477(2)° β=88.693(2)° γ=110.189(3)°
None
C34H36O2.3(C3H7NO).1(C2H6OS)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=9.0858(2)Å b=9.0547(2)Å c=14.7684(4)Å
α=107.1440(10)° β=91.5270(10)° γ=70.236(2)°
None
C34H36O2.2(C3H7NO).2(C2H6OS)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=9.1425(3)Å b=9.1730(3)Å c=14.273(1)Å
α=71.356(1)° β=81.229(1)° γ=69.938(1)°
None
C34H36O2.1(C3H7NO).3(C2H6OS)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=9.0460(2)Å b=9.1291(2)Å c=14.4090(10)Å
α=72.5590(10)° β=80.1320(10)° γ=71.486(2)°
None
C34H36O2.4(C2H6OS)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=9.0359(3)Å b=9.1353(3)Å c=14.4126(6)Å
α=72.9810(10)° β=80.0860(10)° γ=71.631(2)°
None
C34H36O2.2(C3H7NO).2(C3H6O)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=8.99320(10)Å b=9.16740(10)Å c=14.3817(2)Å
α=108.3260(10)° β=92.8080(10)° γ=70.8860(10)°
None
C34H36O2.4(C3H6O)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=8.9057(2)Å b=26.9049(6)Å c=9.1615(2)Å
α=90.00° β=108.5900(10)° γ=90.00°
None
C34H36O2.2(C2H6OS).2(C3H6O)
Journal of the Chemical Society, Perkin Transactions 2 (2002) 12 1973
a=8.9424(18)Å b=9.1788(18)Å c=14.345(3)Å
α=72.25(3)° β=79.80(3)° γ=71.09(3)°
1,1,6,6-tetraphenylhexa-2,4-diyne-1,6-diol dimethyl formamide clathrate
C30H22O2.2(C3H7NO)
CrystEngComm (2003) 5, 28 150
a=11.564(2)Å b=16.393(3)Å c=16.793(3)Å
α=90.00° β=90.00° γ=90.00°
1,1,6,6-tetraphenylhexa-2,4-diyne-1,6-diol dimethylsulphoxide clathrate
C30H22O2.2(C2H6SO)
CrystEngComm (2003) 5, 28 150
a=11.377(2)Å b=15.982(3)Å c=16.191(3)Å
α=90.00° β=90.00° γ=90.00°
None
C30H18F2O2.C5H8O1
CrystEngComm (2004) 6, 2 1
a=8.7846(1)Å b=12.3272(2)Å c=13.4594(2)Å
α=70.080(1)° β=76.153(1)° γ=83.096(1)°
None
C30H18F2O2.C1H2CL2
CrystEngComm (2004) 6, 2 1
a=9.0486(1)Å b=19.3364(2)Å c=14.4056(2)Å
α=90.00° β=95.365(1)° γ=90.00°
None
C30H18F2O2
CrystEngComm (2004) 6, 2 1
a=12.8638(2)Å b=15.8214(2)Å c=16.1334(2)Å
α=88.140(1)° β=88.037(1)° γ=84.747(1)°
1 ?
C35H28O3
Journal of the Chemical Society, Perkin Transactions 2 (2001) 6 861
a=8.6441(5)Å b=12.3085(8)Å c=13.7443(9)Å
α=109.514(3)° β=94.460(3)° γ=104.182(3)°
2 ?
C34H28O3S
Journal of the Chemical Society, Perkin Transactions 2 (2001) 6 861
a=8.5651(3)Å b=12.4402(4)Å c=13.8939(3)Å
α=109.148(2)° β=93.849(2)° γ=104.6200(10)°
4 ?
C38H38O4
Journal of the Chemical Society, Perkin Transactions 2 (2001) 6 861
a=8.3480(10)Å b=9.2270(10)Å c=10.369(2)Å
α=96.095(8)° β=96.159(8)° γ=106.679(7)°
None
C76H88O16S4.5(C6H7N)
CrystEngComm (2006) 8, 3 275
a=13.6878(2)Å b=16.3438(3)Å c=22.3279(5)Å
α=77.8920(10)° β=86.0920(10)° γ=83.9360(10)°
None
C76H88O16S4.4.5(C6H7N).0.5(H2O)
CrystEngComm (2006) 8, 3 275
a=44.8472(3)Å b=20.7901(2)Å c=23.3348(2)Å
α=90.00° β=117.2390(10)° γ=90.00°
Nevirapine-glutaric acid 1:1 co-crystal
C15H14N4O,C5H8O4
CrystEngComm (2012) 14, 7 2541
a=7.363(4)Å b=12.292(6)Å c=12.305(6)Å
α=118.571(8)° β=90.144(9)° γ=98.023(8)°
Nevirapine-maleic acid 1:1 co-crystal
C15H14N4O,C4H4O4
CrystEngComm (2012) 14, 7 2541
a=7.4001(5)Å b=10.4599(7)Å c=23.2561(16)Å
α=90.00° β=98.9680(10)° γ=90.00°
Nevirapine-rac-tartaric acid 1:1 co-crystal
C15H14N4O,C4H6O6
CrystEngComm (2012) 14, 7 2541
a=9.877(2)Å b=19.286(4)Å c=9.6971(19)Å
α=90.00° β=90.66(3)° γ=90.00°
Nevirapine-saccharin 2:1 cocrystal
2(C15H14N4O),C7H5NO3S
CrystEngComm (2012) 14, 7 2541
a=9.5649(5)Å b=13.8069(7)Å c=13.8726(7)Å
α=64.090(3)° β=79.292(2)° γ=82.686(2)°
Nevirapine-salicylic acid 2:1 co-crystal
2(C15H14N4O),C7H6O3
CrystEngComm (2012) 14, 7 2541
a=11.1549(14)Å b=12.6194(15)Å c=13.4644(16)Å
α=113.374(2)° β=99.133(2)° γ=107.324(2)°
None
C34H36O2.1(C3H7NO).3(C2H6OS)
Chemical Communications (2001) 20 2128
a=9.0460(2)Å b=9.1291(2)Å c=14.4090(10)Å
α=72.5590(10)° β=80.1320(10)° γ=71.486(2)°
3 ?
C34.42H28O3S0.58
Journal of the Chemical Society, Perkin Transactions 2 (2001) 6 861
a=8.5652(2)Å b=12.4265(3)Å c=13.8868(3)Å
α=109.155(2)° β=93.853(3)° γ=104.6010(10)°
None
C76H88O16S4.6.5(C6H7N).2(H2O)
CrystEngComm (2006) 8, 3 275
a=16.93660(10)Å b=17.9477(2)Å c=19.4997(2)Å
α=104.4950(10)° β=96.6710(10)° γ=105.44°
Clevudine (Form 2)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=8.9716(9)Å b=5.3099(5)Å c=11.8624(11)Å
α=90° β=105.980(2)° γ=90°
Clevudine (Form 1)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=10.3584(10)Å b=10.8540(10)Å c=10.4469(10)Å
α=90° β=108.403(2)° γ=90°
Clevudine (Form 3)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=10.4391(13)Å b=16.017(2)Å c=13.8687(18)Å
α=90° β=101.604(2)° γ=90°
Bis(Beta-cyclodextrin) bis(4-hydroxybenzoic acid methyl ester) clathrate hydrate (triclinic form)
(C42H70O35)2.(C8H8O3)2.28H2O
Chemical communications (Cambridge, England) (2003) 16 2058-2059
a=18.0187(3)Å b=15.3431(4)Å c=15.4140(3)Å
α=103.464(1)° β=113.122(1)° γ=99.254(1)°
Bis(beta-cyclodextrin) bis(4-hydroxybenzoic acid methyl ester) clathrate hydrate (monoclinic form)
C42H70O35.C8H8O3.7.2H2O
Chemical communications (Cambridge, England) (2003) 16 2058-2059
a=18.8632(4)Å b=24.4542(5)Å c=15.5942(5)Å
α=90.00° β=110.668(1)° γ=90.00°
Octakis(2,3,6-tri-O-acetyl)-gamma-cyclodextrin.2(ethanol).H2O
(C96H128O64).2(C2H5OH).H2O
Chemical communications (Cambridge, England) (2007) 12 1221-1223
a=25.0841(1)Å b=25.0841(1)Å c=38.2760(2)Å
α=90.00° β=90.00° γ=90.00°
Octakis(2,3,6-tri-O-acetyl)-gamma-cyclodextrin sesqui(isopropanolate)monohydrate
C96H128O64.C4.5H12O1.5.H2O
Chemical communications (Cambridge, England) (2007) 12 1221-1223
a=25.0996(1)Å b=25.0996(1)Å c=38.1856(2)Å
α=90.00° β=90.00° γ=90.00°
Isonicotinamide
C6H6N2O1
Chem.Commun. (2011) 47, 1530
a=10.1603(7)Å b=7.3231(5)Å c=15.8720(6)Å
α=90.00° β=90.00° γ=90.00°
Nicotinamide
C6H6N2O1
Chem.Commun. (2011) 47, 1530
a=15.0634(5)Å b=10.6976(4)Å c=15.2067(5)Å
α=90.00° β=102.188(2)° γ=90.00°
((R)-1-phenylethylammonium).((2S)-[2-(4-isobutylphenyl)propanoate])
C13H17O2,C8H12N
CrystEngComm (2010) 12, 11 3634
a=6.8664(5)Å b=12.4548(12)Å c=23.4659(10)Å
α=90° β=90° γ=90°
((R)-1-phenylethylammonium).(2-(2-(2,6-dichlorophenylamino)phenyl)acetate)
C14H10Cl2NO2,C8H12N
CrystEngComm (2010) 12, 11 3634
a=12.499(5)Å b=6.8934(15)Å c=13.411(6)Å
α=90° β=113.73(3)° γ=90°
((R)-1-phenylethylammonium)). (2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylate)
C13H8F3N2O2,C8H12N
CrystEngComm (2010) 12, 11 3634
a=12.4158(6)Å b=5.5535(2)Å c=28.1619(14)Å
α=90° β=94.203(2)° γ=90°
9-phenylfluoren-9-ol 4-methylcyclohexylamine clathrate
C26H29NO
CrystEngComm (2003) 5, 62 351
a=8.7451(17)Å b=11.472(2)Å c=12.336(3)Å
α=100.72(3)° β=96.13(3)° γ=111.23(3)°
9-phenylfluoren-9-ol 4-methylcyclohexylamine clathrate
C26H29NO
CrystEngComm (2003) 5, 62 351
a=11.3947(2)Å b=15.7982(4)Å c=18.4861(5)Å
α=91.028(1)° β=99.107(1)° γ=93.377(2)°
None
C40H32N2O2.C4H8O1
Journal of the Chemical Society, Perkin Transactions 2 (2000) 4 865
a=9.525(2)Å b=14.705(3)Å c=24.448(5)Å
α=90.00° β=90.00° γ=90.00°
MMP
C18H17N3O3S
CrystEngComm (2014) 16, 26 5781
a=14.0063(3)Å b=16.8616(4)Å c=7.8007(5)Å
α=90.00° β=105.4020(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. hexanedioic acid
2(C18H17N3O3S1),C6H10O4
CrystEngComm (2014) 16, 26 5781
a=10.4542(7)Å b=10.7365(7)Å c=19.2796(12)Å
α=92.4070(10)° β=96.173(2)° γ=105.2470(10)°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine.(E)-butenedioate methanolate
C18H18N3O3S,C4H3O4,C1H4O
CrystEngComm (2014) 16, 26 5781
a=5.411(2)Å b=11.572(5)Å c=18.486(8)Å
α=87.456(8)° β=89.447(7)° γ=84.076(8)°
007 oxalic acid hydrate salt
C18H18N3O3S,0.5(C2O4),4(H2O)
CrystEngComm (2014) 16, 26 5781
a=18.581(2)Å b=5.1754(7)Å c=23.326(3)Å
α=90.00° β=106.774(2)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. 2H-1lamda6,2-benzothiazol-1,1,3-trione salt hydrate
C18H18N3O3S1,C7H3N1O3S1,2.48(H2O1)
CrystEngComm (2014) 16, 26 5781
a=13.4221(6)Å b=16.7460(8)Å c=25.6251(12)Å
α=90.00° β=99.4440(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. 2-hydroxybenzoate salt hydrate
C18H18N3O3S,C7H5O3S,H2O1
CrystEngComm (2014) 16, 26 5781
a=13.2320(8)Å b=11.6031(7)Å c=16.5449(10)Å
α=90.00° β=110.9770(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. octanedioate salt
C18H18N3O3S1,C8H13O4
CrystEngComm (2014) 16, 26 5781
a=5.4192(7)Å b=12.1987(15)Å c=19.705(3)Å
α=75.627(2)° β=88.814(2)° γ=89.651(2)°
C32H26O2.5
C32H26O2.5
Journal of the Chemical Society, Perkin Transactions 2 (2001) 11 2119
a=21.959(2)Å b=13.7230(10)Å c=17.1490(10)Å
α=90.00° β=108.216(4)° γ=90.00°
C38H30O4
C38H30O4
Journal of the Chemical Society, Perkin Transactions 2 (2001) 11 2119
a=8.3054(2)Å b=15.3908(4)Å c=11.4520(3)Å
α=90.00° β=94.8920(10)° γ=90.00°
C38H30O4
C38H30O4
Journal of the Chemical Society, Perkin Transactions 2 (2001) 11 2119
a=8.2907(4)Å b=16.0716(9)Å c=11.4225(4)Å
α=90.00° β=93.061(3)° γ=90.00°
C36H28O2S2.53
C36H28O2S2.53
Journal of the Chemical Society, Perkin Transactions 2 (2001) 11 2119
a=8.2043(2)Å b=16.0186(5)Å c=11.4831(3)Å
α=90.00° β=94.521(2)° γ=90.00°
C42H60N12O12S2
C42H60N12O12S2
Acta Crystallographica Section B (1993) 49, 4 760-768
a=16.304(6)Å b=20.321(8)Å c=15.939(6)Å
α=90° β=102.25(2)° γ=90°
C23H36N4O8S2
C23H36N4O8S2
Acta Crystallographica Section B (1993) 49, 4 760-768
a=8.355(4)Å b=40.104(4)Å c=9.339(2)Å
α=90° β=111.13(3)° γ=90°
C38H54N10O10S2
C38H54N10O10S2
Acta Crystallographica Section B (1993) 49, 4 760-768
a=13.558(3)Å b=14.570(3)Å c=11.4040(10)Å
α=90° β=95.380(10)° γ=90°
C24H42N4,Cl6Sn1
C24H42N4,Cl6Sn1
Acta Crystallographica Section C (1993) 49, 1 22-26
a=10.002(2)Å b=10.6390(10)Å c=15.616(4)Å
α=90° β=102.05(2)° γ=90°
C24H42N4,Cl6Sn1
C24H42N4,Cl6Sn1
Acta Crystallographica Section C (1993) 49, 1 22-26
a=9.998(2)Å b=10.6490(10)Å c=15.637(4)Å
α=90° β=102.03(2)° γ=90°
C6H17Cl5N2O2Sn
C6H17Cl5N2O2Sn
Acta Crystallographica Section C (1993) 49, 1 26-30
a=10.7880(10)Å b=18.5600(10)Å c=8.1580(10)Å
α=90° β=96.180(10)° γ=90°
3-ethyl-5-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalene)-methynyl]- 2,4-triazolidindione
C20H25NO2S
Acta Crystallographica Section C (1999) 55, 6 1027-1029
a=10.4120(10)Å b=8.5160(10)Å c=21.5560(10)Å
α=90.00° β=101.223(10)° γ=90.00°
Sulfasalazine
C18H14N4O5S1
Acta Crystallographica Section C (2001) 57, 4 435-436
a=7.0170(10)Å b=7.3070(10)Å c=18.0910(10)Å
α=94.673(3)° β=92.059(3)° γ=106.633(3)°
None
C10H9ClO3
The Journal of organic chemistry (2016) 81, 1 109-120
a=5.1208(4)Å b=7.8498(8)Å c=11.9863(12)Å
α=99.256(4)° β=91.114(7)° γ=100.217(7)°
None
C23H21N3O5
Beilstein Journal of Organic Chemistry (2016) 12, 2503
a=8.9685(5)Å b=10.6487(7)Å c=11.0785(7)Å
α=93.4800(10)° β=95.8860(10)° γ=109.3060(10)°
(+)-(2R,3R)-tetraphenylbutane-1,2,3,4-tetraol/3-methylcyclohexanone (1:1)
C28H26O4,C7H12O
The Journal of organic chemistry (2015) 80, 14 7184-7192
a=12.4493(6)Å b=8.2368(4)Å c=13.9466(7)Å
α=90.00° β=95.843(2)° γ=90.00°
None
C28H26O4,C7H12O1
The Journal of organic chemistry (2015) 80, 14 7184-7192
a=8.181(2)Å b=9.952(3)Å c=10.163(3)Å
α=79.296(6)° β=68.813(5)° γ=65.825(5)°